Open AccessBosutinib‐associated interstitial lung disease and pleural effusion: A case report and literature review
Author(s) -
Liu Qiuying Selina,
Ass'ad Nour Ali,
Arana Yi Cecilia
Publication year - 2021
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.3164
Subject(s) - bosutinib , medicine , interstitial lung disease , pleural effusion , tyrosine kinase inhibitor , myeloid leukemia , lung , pathology , oncology , imatinib , nilotinib , cancer
Bosutinib is a tyrosine kinase inhibitor approved for the management of chronic myeloid leukemia (CML). Interstitial lung disease and pleural effusion are pulmonary side effects of TKIs rarely associated with bosutinib treatment.